REPL — Replimune Group, Inc.

REPL

HOLD / NEUTRALNeutral

Composite

51.40

Technical

80.90

Fundamental

31.70

Rank

—

Price

16.06

Hurst

0.42

As of

Oct 29, 2026

Daily

Replimune Group, Inc.

HealthcareBiotechnology

Replimune Group is a biotechnology company in clinical development stages that creates oncolytic immunotherapy candidates intended to treat cancer by stimulating immune system activity against tumors. The company's lead program, RP1, is a modified herpes simplex virus designed to express two therapeutic proteins for solid tumors. It is also developing RP2, which targets immune checkpoint inhibition through an antibody-like molecule. The firm operates in the United States and United Kingdom.

Market cap

$1.7B

P/E (trailing)

—

P/E (forward)

-26.25

PEG ratio

—

Dividend yield

0.00%

Beta

0.94

52w range

1.50 – 18.27

Return on equity

-115.80%

Profit margin

0.00%

Revenue growth

—

Earnings growth

—

Price history

1Y: 17.61 (+81.0%) · range 1.70–17.61

Cycle position

84/ 100 cycle scoreEXIT ZONE

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 2 · NOT READY · exit proximity 78

Conviction

29/ 100 · maturity 29%

VScore.1614

Buildup.2870

EMA entry setup.352

Fundamentals.2132

Volume profile

POC

5.05

Price vs POC

+248.8%

Overhead supply

Runway

open sky

Value area 3.74–12.46 · 0% of 119d volume overhead · clean runway

Contributing sources

Source	Score	Last seen
earnings-surprise	0.933	Oct 30, 2026

Forward returns

Not yet labeled — the study prices these as positions mature.